uniQure N.V. QURE
22.79 USD +1.09 (+5.02%)
At closeNov 10, 2026, 7:38 AM EST
22.85 +0.06 +0.26%
Pre-market · Nov 10, 7:38 AM ET
21.13 Day range 23.01
8.73 52-week range 51.72
- YTD
- -4.76%
- 1 year
- -12.85%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 60.21 +164.2% upside
Now 22.79
- Target (low)
- 28.01
- Target (mean)
- 60.21
- Target (high)
- 91.68
Ratings (0m) 13 11 buy · 2 hold · 0 sell
- Strong buy1
- Buy10
- Hold2
- Sell0
- Strong sell0
Recommendation trend
- This month 13
- 1 month ago 13
- 2 months ago 12
- 3 months ago 12
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.745 | -0.838 – -0.499 | -0.47393 | -57.2% | 5.91M | +25.5% | 6 |
| Next quarter | -0.9954 | -1.39 – -0.838 | -0.72658 | -37.0% | 4.54M | +49.2% | 5 |
| Current year | -3.30 | -3.47 – -3.12 | -2.93 | -12.8% | 18.96M | +39.2% | 8 |
| Next year | -2.84 | -3.83 – -0.524 | -3.30 | +14.0% | 112.00M | +490.7% | 10 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 5, 2026 | Barclays | Downgrade | Overweight | Equal-Weight |
| Oct 2, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Sep 30, 2026 | Goldman Sachs | Maintained | Neutral | Neutral |
| Jul 30, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Jul 30, 2026 | Wolfe Research | Upgrade | Peer Perform | Outperform |
| Jul 30, 2026 | Barclays | Maintained | Overweight | Overweight |
| Jun 29, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jun 25, 2026 | Mizuho | Maintained | Outperform | Outperform |
| Jun 18, 2026 | Barclays | Upgrade | Equal-Weight | Overweight |
| Jun 18, 2026 | Goldman Sachs | Maintained | Neutral | Neutral |
| Jun 18, 2026 | Leerink Partners | Maintained | Outperform | Outperform |
| Jun 18, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| May 6, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Apr 30, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Apr 20, 2026 | Goldman Sachs | Maintained | Neutral | Neutral |
| Mar 23, 2026 | Barclays | Maintained | Equal-Weight | Equal-Weight |
| Mar 11, 2026 | Mizuho | Upgrade | Neutral | Outperform |
| Mar 10, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 9, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Mar 9, 2026 | RBC Capital | Upgrade | Sector Perform | Outperform |
| Mar 9, 2026 | Wells Fargo | Upgrade | Equal-Weight | Overweight |
| Mar 3, 2026 | Goldman Sachs | Maintained | Neutral | Neutral |
| Mar 3, 2026 | Wells Fargo | Downgrade | Overweight | Equal-Weight |
| Mar 3, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Mar 3, 2026 | Mizuho | Downgrade | Outperform | Neutral |
| Mar 2, 2026 | Leerink Partners | Maintained | Outperform | Outperform |
| Mar 2, 2026 | Cantor Fitzgerald | Upgrade | Overweight | Neutral |
| Feb 24, 2026 | Wolfe Research | Initiated | — | Peer Perform |
| Feb 10, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jan 28, 2026 | Barclays | Initiated | — | Equal-Weight |
